Entera Appoints Global BioPharma Executive Laura Hamill to Its Board of Directors, Expanding Commercial Expertise
Key Highlights
- ➤Laura Hamill joins Entera’s board effective December 1, 2026
- ➤Hamill brings more than 35 years of global commercial leadership experience
- ➤EB613 enters late-stage clinical execution and commercial preparedness
- ➤Hamill previously led Gilead commercial operations generating $22 billion annually
- ➤Yonatan Malca departs Entera’s board after 16 years of service
Expert Statements
Miranda Toledano, Chief Executive Officer of Entera
“I am delighted to welcome Laura to our Board as Entera enters an important new chapter of late-stage clinical execution, commercial preparedness for EB613 and advancement of our broader pipeline.”
Miranda Toledano, Chief Executive Officer of Entera
“Laura is an exceptional leader with vast experience stewarding multi-billion dollar global therapeutic franchises. Her perspective will be invaluable as we think strategically about the potential of EB613 and our oral peptide platform.”
Miranda Toledano, Chief Executive Officer of Entera
“I would also like to express my sincere gratitude to Yonatan for his 16 years of dedicated service to Entera.”
Laura Hamill, Biopharmaceutical executive and Entera board member
“Entera has built a unique oral peptide pipeline with the potential to transform how important therapies are delivered to patients.”
Laura Hamill, Biopharmaceutical executive and Entera board member
“I am particularly inspired by the potential of EB613 in osteoporosis and the opportunity to help millions of women preserve their bone health and maintain active, vibrant lives.”
Laura Hamill, Biopharmaceutical executive and Entera board member
“I am excited to join the Board at this important stage and support Entera as it works to advance EB613 and realize the broader potential of Entera’s oral peptide platform.”
TEL AVIV, Israel, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced the appointment of biopharmaceutical executive Laura Hamill to its Board of Directors, effective December 1, 2026. Ms. Hamill brings more than 35 years of global commercial, market access and business leadership experience across multiple therapeutic areas. She succeeds Yonatan Malca, who is stepping down from the Board.
“I am delighted to welcome Laura to our Board as Entera enters an important new chapter of late-stage clinical execution, commercial preparedness for EB613 and advancement of our broader pipeline,” said Miranda Toledano, Chief Executive Officer of Entera. “Laura is an exceptional leader with vast experience stewarding multi-billion dollar global therapeutic franchises. Her perspective will be invaluable as we think strategically about the potential of EB613 and our oral peptide platform.” “I would also like to express my sincere gratitude to Yonatan for his 16 years of dedicated service to Entera,” Ms. Toledano continued. “His leadership and commitment have helped guide the Company from its inception through a period of meaningful growth and transformation.”
Get started
Create a free account to read the full story.